<DOC>
	<DOCNO>NCT02781311</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy oral administration setipiprant tablet 1000 mg twice daily ( BID ) relative placebo active comparator , finasteride 1 mg daily , 18 41 year old male androgenetic alopecia ( AGA ) .</brief_summary>
	<brief_title>Phase 2A Study Setipiprant Tablets Androgenetic Alopecia Males</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Participant androgenetic alopecia ( AGA ) Participant agree maintain current hair care regimen , refrain hair weaving , hair colorants dye nonstudy hair growth product study . History hair loss reason AGA Scarring scalp condition disease scalp , hair hair shaft Use product within 6 month study start use continuously least 1 month could impact hair growth Hairweaving within 6 month Use hair colorants dye within 6 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>